Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
Sponsor: Wenjin Yin
View on ClinicalTrials.gov
Summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Official title: Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
118
Start Date
2025-08-28
Completion Date
2029-02
Last Updated
2025-11-18
Healthy Volunteers
No
Conditions
Interventions
DRUG
Trastuzumab deruxtecan
Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China